Home  »  Stock   »  Why is iTeos Therapeutics Inc. (ITOS) down -43.25%...

Why is iTeos Therapeutics Inc. (ITOS) down -43.25% from the day 1 this year?

Let’s start up with the current stock price of iTeos Therapeutics Inc. (ITOS), which is $21.65 to be very precise. The Stock rose vividly during the last session to $21.86 after opening rate of $19.27 while the lowest price it went was recorded $18.84 before closing at $19.31.Recently in News on January 9, 2023, iTeos Provides Business Updates and Clinical Development Plans for 2023. – 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant. You can read further details here

iTeos Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $21.86 on 01/19/23, with the lowest value was $17.07 for the same time period, recorded on 01/05/23.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


iTeos Therapeutics Inc. (ITOS) full year performance was -43.25%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, iTeos Therapeutics Inc. shares are logging -44.53% during the 52-week period from high price, and 33.56% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $16.21 and $39.03.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 664736 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the iTeos Therapeutics Inc. (ITOS) recorded performance in the market was 10.86%, having the revenues showcasing 17.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 765.33M, as it employees total of 94 workers.

The Analysts eye on iTeos Therapeutics Inc. (ITOS)

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 19.75, with a change in the price was noted -2.25. In a similar fashion, iTeos Therapeutics Inc. posted a movement of -9.41% for the period of last 100 days, recording 336,163 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ITOS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of iTeos Therapeutics Inc. (ITOS)

Raw Stochastic average of iTeos Therapeutics Inc. in the period of last 50 days is set at 90.38%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 96.10%. In the last 20 days, the company’s Stochastic %K was 70.83% and its Stochastic %D was recorded 60.08%.

Considering, the past performance of iTeos Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 10.86%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -20.32%, alongside a downfall of -43.25% for the period of the last 12 months. The shares increased approximately by 12.76% in the 7-day charts and went up by 2.32% in the period of the last 30 days. Common stock shares were driven by 17.15% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts